Cancer Genetics, Inc. Announces Full Exercise of Over-Allotment Option
RUTHERFORD, N.J.--(BUSINESS WIRE)-- Cancer Genetics, Inc. (OTCQB: CGIX), a diagnostics company focused on developing genomic-based, oncology tests and services, today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 90,000 shares of its common stock, at a price to the public of $10.00 per share, in connection with its previously announced underwritten initial public offering of 600,000 shares of common stock, bringing expected total gross proceeds from the offering to $6,900,000, before underwriting discounts and commissions and other offering expenses payable by Cancer Genetics.
Aegis Capital Corp. is acting as sole book-running manager for the offering.
Feltl and Company, Inc. is acting as co-manager for the offering.
This offering is being made only by means of a prospectus. Copies of the prospectus relating to this offering may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY 10019, telephone: 212-813-1010, e-mail: email@example.com.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on April 4, 2013. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Cancer Genetics:
Cancer Genetics, Inc. is an early-stage diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve and personalize the diagnosis, prognosis and response to treatment (theranosis) of cancer. The proprietary tests being developed by Cancer Genetics target cancers that are difficult to prognose and predict treatment outcomes by using currently available mainstream techniques. These cancers include hematological, urogenital and HPV-associated cancers. Cancer Genetics recently has begun to provide its proprietary tests and services along with a comprehensive range of non-proprietary oncology-focused tests and laboratory services that it has provided historically to oncologists and pathologists at hospitals, cancer centers and physician offices. Cancer Genetics is currently offering its tests and laboratory services in its 17,936 square foot laboratory located in Rutherford, New Jersey, which has been accredited under the Clinical Laboratory Improvement Amendments of 1988 to perform high complexity testing.
Elizabeth Czerepak, 201-528-9200
Chief Financial Officer
KEYWORDS: United States North America New Jersey